Director, Clinical Trial Liaison West

Kardigan; United States; On-site; USD 140,000 - 230,000; Full time

Job summary

Kardigan, a heart health company, is seeking a Director-level Clinical Trial Liaison to build relationships with investigators and research site staff and to facilitate recruitment of subjects for Kardigan clinical trials.

The CTL will support Global Development clinical study execution as the local field-based representative in one or more regions, and will work with study teams to ensure investigators understand the investigational agents, eligibility criteria, and all study procedures.

Responsibilities

• The Clinical Trial Liaison (CTL) will develop relationships with clinical trial investigators and research site staff to facilitate recruitment of subjects in Kardigan clinical trials.
• The CTL supports Global Development clinical study execution as the local field-based representative for Kardigan in one or more countries/regions supporting clinical development programs.
• The CTL interacts with investigator sites and other parties related to clinical trial execution.
• Depending on trial needs and status, some periods will involve extensive travel, up to 70%, to support site teams, troubleshoot challenges, and foster strong, collaborative relationships.
• The CTL will work in concert Kardigan’s clinical trial teams to ensure that investigators and site staff have a thorough scientific understanding of the investigational agents being used in the study, the trial’s eligibility criteria, and all study procedures.

Job description

Kardigan is a heart health company working to make cardiovascular disease preventable, curable and no longer the leading cause of death in the world.

It is Kardigan’s mission to develop multiple targeted treatments in parallel that bring people with cardiovascular diseases to the cures they deserve.

Led by Tassos Gianakakos, Jay Edelberg, M.D., Ph.D., and Bob McDowell, Ph.D., Kardigan’s co-founders have reunited after leading MyoKardia to discover and develop mavacamten, the first cardiac myosin inhibitor, resulting in an acquisition by Bristol Myers Squibb in 2020.

We have a cutting-edge discovery and translational research platform, a pipeline of late-stage candidates, and an industry-leading team that is driven to improve the lives of patients.

At Kardigan, we are motivated by our values which guide how we work, interact, and achieve our goals. Driven by patients and their families, we are deeply committed to improving the lives of patients and prioritizing their needs above all else. We believe in being authentic—leading with truth to bring out the best in others by creating an environment where every person knows they will be fully accepted. With an eagerness to learn, we encourage the highest levels of curiosity and are open to changing our minds. We are committed to winning as a team with urgency, excellence, and intention, and support each other no matter what role we play or where we sit. Lastly, we strive to enable the impossible because patients are counting on us. We are not afraid to take risks to unlock innovation and advance scientific discoveries.

These values are the foundation of our work, empowering us to make a real difference, every day.

Job Title: CLINICAL TRIAL LIAISON (CTL)

Level: Director

Reports to: Senior Director or above, Clinical Operations

The Clinical Trial Liaison (CTL) will develop relationships with clinical trial investigators and research site staff to facilitate recruitment of subjects in Kardigan clinical trials. The Clinical Trial Liaison (CTL) supports Global Development clinical study execution as the local field-based representative for Kardigan in one or more countries/regions supporting clinical development programs. The CTL interacts with investigator sites and other parties related to clinical trial execution. Depending on trial needs and status, some periods will involve extensive travel, up to 70%, to support site teams, troubleshoot challenges, and foster strong, collaborative relationships.

The CTL provides regional and country specific insights to support study feasibility, site identification and selection, and patient recruitment and retention initiatives. In collaboration with the study team, the CTL both identifies and helps facilitate resolution of investigator site issues.

The CTL will work in concert Kardigan’s clinical trial teams to ensure that investigators and site staff have a thorough scientific understanding of the investigational agents being used in the study, the trial’s eligibility criteria, and all study procedures. Particular attention will be given to assessing the effectiveness of each site’s strategy used to identify potentially eligible subjects. The CTL must also understand how the trial fits into the site’s pattern of treatment for the condition and how any competing